UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Hypoxia: The Cornerstone of Glioblastoma

International journal of molecular sciences, 2021-11, Vol.22 (22), p.12608

2021

Volltextzugriff (PDF)

Resistant mechanisms to BRAF inhibitors in melanoma

Annals of translational medicine, 2016-06, Vol.4 (12), p.237-237

2016

Volltextzugriff (PDF)

Nuclear IGF-1R predicts chemotherapy and targeted therapy resistance in metastatic colorectal cancer

British journal of cancer, 2017-12, Vol.117 (12), p.1777-1786

2017

Volltextzugriff (PDF)

Changes In Serum CXCL13 Levels Are Associated With Outcomes of Colorectal Cancer Patients Undergoing First-Line Oxaliplatin-Based Treatment

Biomedicine & pharmacotherapy, 2024-07, Vol.176, p.116857, Article 116857

2024

Volltextzugriff (PDF)

Efficacy of CT-P6 (trastuzumab biosimilar) versus reference trastuzumab in combination with pertuzumab in HER2-positive early-stage breast cancer: Preclinical and real-life clinical data

Breast (Edinburgh), 2022-04, Vol.62, p.1-9

2022

Volltextzugriff (PDF)

LoVo colon cancer cells resistant to oxaliplatin overexpress c-MET and VEGFR-1 and respond to VEGF with dephosphorylation of c-MET

Molecular carcinogenesis, 2016-05, Vol.55 (5), p.411-419

2016

Volltextzugriff (PDF)

CXC family of chemokines as prognostic or predictive biomarkers and possible drug targets in colorectal cancer

World journal of gastroenterology : WJG, 2018-11, Vol.24 (42), p.4738-4749

2018

Volltextzugriff (PDF)

Epigenetic Homogeneity Within Colorectal Tumors Predicts Shorter Relapse-Free and Overall Survival Times for Patients With Locoregional Cancer

Gastroenterology (New York, N.Y. 1943), 2016-11, Vol.151 (5), p.961-972

2016

Volltextzugriff (PDF)

Curcumin: A Novel Way to Improve Quality of Life for Colorectal Cancer Patients?

International journal of molecular sciences, 2022-11, Vol.23 (22), p.14058

2022

Volltextzugriff (PDF)

Chromatin factors: Ready to roll as biomarkers in metastatic colorectal cancer?

Pharmacological research, 2023-10, Vol.196, p.106924, Article 106924

2023

Volltextzugriff (PDF)

Curcumin: A therapeutic strategy for colorectal cancer?

Seminars in cancer biology, 2021-08, Vol.73, p.321-330

2021

Volltextzugriff (PDF)

Carcinoma-associated fibroblasts affect sensitivity to oxaliplatin and 5FU in colorectal cancer cells

Oncotarget, 2016-09, Vol.7 (37), p.59766-59780

2016

Volltextzugriff (PDF)

PKM2 Subcellular Localization Is Involved in Oxaliplatin Resistance Acquisition in HT29 Human Colorectal Cancer Cell Lines

PloS one, 2015-05, Vol.10 (5), p.e0123830

2015

Volltextzugriff (PDF)

Translational Research Opportunities Regarding Homologous Recombination in Ovarian Cancer

International journal of molecular sciences, 2018-10, Vol.19 (10), p.3249

2018

Volltextzugriff (PDF)

Tumor-Related Molecular Mechanisms of Oxaliplatin Resistance

Molecular cancer therapeutics, 2015-08, Vol.14 (8), p.1767-1776

2015

Volltextzugriff (PDF)

Editorial: Transcriptional Regulation as a Key Player in Cancer Cells Drug Resistance

Frontiers in oncology, 2021-10, Vol.11, p.764506-764506

2021

Volltextzugriff (PDF)

The European Network for Sinonasal Cancer Research (EUSICA) – A pan-European initiative targeting a group of orphan tumours

European journal of cancer (1990), 2024-05, Vol.202, p.113939-113939, Article 113939

2024

Volltextzugriff (PDF)

Epigenetic Inactivation of the BRCA1 Interactor SRBC and Resistance to Oxaliplatin in Colorectal Cancer

JNCI : Journal of the National Cancer Institute, 2014-01, Vol.106 (1), p.djt322

2014

Volltextzugriff (PDF)

ERCC1 and ERCC2 Polymorphisms Predict Clinical Outcomes of Oxaliplatin-Based Chemotherapies in Gastric and Colorectal Cancer: A Systemic Review and Meta-analysis

Clinical cancer research, 2011-03, Vol.17 (6), p.1632-1640

2011

Volltextzugriff (PDF)

Increased levels of copper efflux transporter ATP7B are associated with poor outcome in colorectal cancer patients receiving oxaliplatin‐based chemotherapy

International journal of cancer, 2009-06, Vol.124 (12), p.2905-2910

2009

Volltextzugriff (PDF)

Tumor Expression of Cyclin-Dependent Kinase 5 (Cdk5) Is a Prognostic Biomarker and Predicts Outcome of Oxaliplatin-Treated Metastatic Colorectal Cancer Patients

Cancers, 2019-10, Vol.11 (10), p.1540

2019

Volltextzugriff (PDF)

Curcumin mediates oxaliplatin-acquired resistance reversion in colorectal cancer cell lines through modulation of CXC-Chemokine/NF-κB signalling pathway

Scientific reports, 2016-04, Vol.6 (1), p.24675, Article 24675

2016

Volltextzugriff (PDF)

Chemotactic signaling pathways in prostate cancer: Implications in the tumor microenvironment and as potential therapeutic targets

International review of cell and molecular biology, 2024, Vol.388, p.162

2024

Volltextzugriff (PDF)

A proteomic approach links decreased pyruvate kinase M2 expression to oxaliplatin resistance in patients with colorectal cancer and in human cell lines

Molecular cancer therapeutics, 2009-04, Vol.8 (4), p.771-778

2009

Volltextzugriff (PDF)

Pharmacogenomic approach for the identification of novel determinants of acquired resistance to oxaliplatin in colorectal cancer

Molecular cancer therapeutics, 2009-01, Vol.8 (1), p.194-202

2009

Volltextzugriff (PDF)

1 – 25 von 55

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(51)
Mit Volltextzugriff
(54)

Publikationsform

Artikel
(55)

Sprache

Englisch
(54)
Spanisch
(1)

Erscheinungsjahr

n.n

Thema

Science & Technology
(30)
Life Sciences & Biomedicine
(29)
Humans
(27)
Oncology
(25)
Colorectal Cancer
(19)
Oxaliplatin
(13)
Colorectal Neoplasms - Drug Therapy
(12)
Female
(12)
Male
(12)
Tumors
(12)
Chemotherapy
(10)
Aged
(9)
Cell Line, Tumor
(9)
Colorectal Neoplasms - Genetics
(9)
Colorectal Neoplasms - Pathology
(9)
Middle Aged
(9)
Organoplatinum Compounds - Pharmacology
(9)
Antineoplastic Agents - Pharmacology
(8)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(8)
Biological And Medical Sciences
(7)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Hypoxia: The Cornerstone of Glioblastoma

Resistant mechanisms to BRAF inhibitors in melanoma

Nuclear IGF-1R predicts chemotherapy and targeted therapy resistance in metastatic colorectal cancer

Changes In Serum CXCL13 Levels Are Associated With Outcomes of Colorectal Cancer Patients Undergoing First-Line Oxaliplatin-Based Treatment

Efficacy of CT-P6 (trastuzumab biosimilar) versus reference trastuzumab in combination with pertuzumab in HER2-positive early-stage breast cancer: Preclinical and real-life clinical data

LoVo colon cancer cells resistant to oxaliplatin overexpress c-MET and VEGFR-1 and respond to VEGF with dephosphorylation of c-MET

CXC family of chemokines as prognostic or predictive biomarkers and possible drug targets in colorectal cancer

Epigenetic Homogeneity Within Colorectal Tumors Predicts Shorter Relapse-Free and Overall Survival Times for Patients With Locoregional Cancer

Curcumin: A Novel Way to Improve Quality of Life for Colorectal Cancer Patients?

Chromatin factors: Ready to roll as biomarkers in metastatic colorectal cancer?

Curcumin: A therapeutic strategy for colorectal cancer?

Carcinoma-associated fibroblasts affect sensitivity to oxaliplatin and 5FU in colorectal cancer cells

PKM2 Subcellular Localization Is Involved in Oxaliplatin Resistance Acquisition in HT29 Human Colorectal Cancer Cell Lines

Translational Research Opportunities Regarding Homologous Recombination in Ovarian Cancer

Tumor-Related Molecular Mechanisms of Oxaliplatin Resistance

Editorial: Transcriptional Regulation as a Key Player in Cancer Cells Drug Resistance

The European Network for Sinonasal Cancer Research (EUSICA) – A pan-European initiative targeting a group of orphan tumours

Epigenetic Inactivation of the BRCA1 Interactor SRBC and Resistance to Oxaliplatin in Colorectal Cancer

ERCC1 and ERCC2 Polymorphisms Predict Clinical Outcomes of Oxaliplatin-Based Chemotherapies in Gastric and Colorectal Cancer: A Systemic Review and Meta-analysis

Increased levels of copper efflux transporter ATP7B are associated with poor outcome in colorectal cancer patients receiving oxaliplatin‐based chemotherapy

Tumor Expression of Cyclin-Dependent Kinase 5 (Cdk5) Is a Prognostic Biomarker and Predicts Outcome of Oxaliplatin-Treated Metastatic Colorectal Cancer Patients

Curcumin mediates oxaliplatin-acquired resistance reversion in colorectal cancer cell lines through modulation of CXC-Chemokine/NF-κB signalling pathway

Chemotactic signaling pathways in prostate cancer: Implications in the tumor microenvironment and as potential therapeutic targets

A proteomic approach links decreased pyruvate kinase M2 expression to oxaliplatin resistance in patients with colorectal cancer and in human cell lines

Pharmacogenomic approach for the identification of novel determinants of acquired resistance to oxaliplatin in colorectal cancer

Suchergebnisse filtern